SciSparc announced it has signed an agreement with Tikun Olam Cannbit Pharmaceuticals to supply CBD-rich oil from Cannbit strains by, to be used as part of its proprietary SCI-210 treatment, which is a combination of CBD and CannAmide. SCI-210 treatment will be used in the Company’s clinical trial on children with autism spectrum disorder. The Trial will be conducted at the Soroka University Medical Center, led by Prof. Gal Meiri, head of the Soroka Preschool Psychiatry Unit. The Company has already secured approvals from the Israeli Ministry of Health as well as the Ethics Committee of the Soroka University Medical Center to conduct the Company’s clinical trial. The Trial will evaluate the safety, tolerability and efficacy of SciSparc’s drug candidate SCI-210, a proprietary combination of cannabidiol and CannAmide, in comparison to CBD monotherapy in children with ASD. The study design is a 20-week, randomized double-blind placebo-controlled with cross-over clinical trial on 60 children. The trial has three primary efficacy end points: the Aberrant Behavior Checklist-Community parent questionnaire; the Clinical Global Impressions-Improvement performed by a clinician; and the effective therapeutic dose.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on SPRC:
- SciSparc Signs Agreement for the Supply of CBD-rich Cannabis Oil for its Clinical Trial on Children with Autism Spectrum Disorder
- Jeffs’ Brands enters agreement to acquire 49% of SciSparc Nutraceuticals
- SciSparc Signs a Definitive Agreement to Sell 49% interest in its Subsidiary that Owns Wellution for $2.5 million
- SciSparc to sell 49% interest in subsidiary to Jeff Brands subsidiary for $2.5M
- SciSparc, Clearmind reveal three combinations of psychedelic-based compounds
